A Narrative Review of the Clinical, Humanistic, and Economic Value of Pembrolizumab-Based Immunotherapy for the Treatment of Breast and Gynecologic Cancers
Open Access
- 25 October 2024
- journal article
- review article
- Published by Springer Nature in Oncology and Therapy
- Vol. 12 (4) , 701-734
Abstract
Breast and gynecologic cancers are common across the world and are associated with substantial societal and economic burden. Pembrolizumab was among the first immune checkpoint inhibitors targeting programmed cell death protein 1 to be approved for the treatment of patients with triple-negative breast cancer, cervical cancer, and endometrial cancer. Recent clinical trials have established pembrolizumab regimens as a standard of care treatment for these tumor types. Clinical data are further supported by patient-reported outcome, cost-effectiveness, and real-world evidence. Pembrolizumab monotherapy and combination regimens do not negatively influence health-related quality of life and are cost-effective relative to comparators. Ongoing phase 3 studies with pembrolizumab will expand the current understanding of its use in breast and gynecologic cancers. Several of these studies are in patients with early-stage disease with the hope of curing patients. The main objective of this review is to summarize the clinical, humanistic, and economic value of pembrolizumab in these settings and to describe the future challenges for patients, caregivers, clinicians, and payers.Keywords
Funding Information
- Funding for this research was provided by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
This publication has 145 references indexed in Scilit:
- Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United StatesAdvances in Therapy, 2023
- The Economic Burden of Recurrence in Triple-Negative Breast Cancer Among Working Age Patients in the United StatesAdvances in Therapy, 2021
- Prevalence of cognitive impairment and change in patients with breast cancer: A systematic review of longitudinal studiesPsycho-Oncology, 2021
- Quality of life and mental health in breast cancer survivors compared with non-cancer controls: a study of patient-reported outcomes in the United KingdomJournal of Cancer Survivorship, 2020
- Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast CancerJAMA Oncology, 2020
- Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast CancerJAMA Oncology, 2020
- Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian CarcinomaJAMA Oncology, 2019
- Ten‐year recurrence rates for breast cancer subtypes in the Netherlands: A large population‐based studyInternational Journal of Cancer, 2018
- Racial disparities in BRCA testing and cancer risk management across a population‐based sample of young breast cancer survivorsCancer, 2017
- Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trialsCancer, 2009